pros and cons of semaglutide Day 2: Wegovy (Semaglutide 2.4 mg weekly injection) Class: GLP-1 receptor agonist Avg Weight Loss: ~15% baseline weight Dosing: Weekly subcutaneous injection FDA Approved: June 2021 for chronic weight management What to Know About Semaglutide:

Case report and literature review

can be serious if not treated promptly

Louis Bariatrics, both options are part of a broader strategy, not competing choices, but tools that can be used at different points in a patients journey

[DOI] [PubMed] [Google Scholar] 26.Olayaki L.A., Irekpita J.E., Yakubu M.T., Ojo O.O

Semaglutide, the weight-loss and diabetes drug better known as Ozempic and Wegovy, will soon be available in generic form for 40% of the worlds population

Serious but rare risks (both medications): Pancreatitis Gallbladder disease Acute kidney injury (in severe dehydration cases) Black box warning: Both carry a thyroid C-cell tumor warning based on rodent studies